Surrozen expects to start Phase 1 trials for SZN-1326 and SZN-043 in Q3 2022; nominates SZN-413 candidate

Surrozen, Inc./DE

Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.
Nominated SZN-413, a mono Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD and diabetic retinopathies.
None of the product candidates have been tested in humans or gained regulatory approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.